Wellmarker Bio Entered into a Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 + Keytruda (pembrolizumab) for Non-Small Cell Lung Cancer
Shots:
- The companies collaborated to evaluate WM-A1-3389 + MSD's Keytruda (anti-PD-1 therapy) in the P-I trial for NSCLC patients with low or no PD-L1 expression. Additionally, WMBIO will be responsible to sponsor the P-I clinical trial
- WM-A1-3389 is a novel therapeutic Ab targeting a new immune checkpoint protein discovered by Wellmarker Bio which demonstrated efficacy across different PBMC humanized models
- In preclinical mouse models incl. PD-1-resistant CT26 and LLC-1 mouse models, WM-A1-3389, and anti-PD-1 Ab showed additive benefits. The company plans to advance the Ab beyond NSCLC and develop it into a treatment for other solid tumors
Ref: PRNewswire | Image: Wellmarker Bio
Related News:- Antengene Entered into a Clinical Collaboration with MSD to Evaluate ATG-037 + Keytruda (pembrolizumab) for Solid Tumors
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
